RxSight (NASDAQ:RXST) Stock Price Crosses Below 50 Day Moving Average - Time to Sell?

RxSight logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • RxSight shares fell below their 50-day moving average: The stock traded as low as $4.58 and last changed hands at $4.61, versus a 50-day average of $4.93.
  • Quarterly results missed analyst expectations: RxSight reported a loss of $0.39 per share, compared with estimates of a $0.31 loss, and revenue of $24.59 million versus a $27.19 million consensus.
  • Analyst sentiment is broadly neutral: Two analysts rate the stock Buy, seven Hold and two Sell; the consensus rating is Hold, with a $6.94 price target.
  • Five stocks we like better than RxSight.

RxSight, Inc. (NASDAQ:RXST - Get Free Report) crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $4.93 and traded as low as $4.58. RxSight shares last traded at $4.61, with a volume of 798,387 shares trading hands.

Wall Street Analysts Forecast Growth

RXST has been the topic of several research reports. UBS Group upped their price objective on shares of RxSight from $5.50 to $6.30 and gave the company a "neutral" rating in a research note on Thursday, August 6th. Wall Street Zen upgraded RxSight from a "sell" rating to a "hold" rating in a report on Saturday, November 7th. Wells Fargo & Company decreased their target price on RxSight from $9.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 4th. Stifel Nicolaus dropped their price target on shares of RxSight from $8.00 to $7.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Finally, Weiss Ratings upgraded shares of RxSight from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, November 12th. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, RxSight presently has a consensus rating of "Hold" and a consensus price target of $6.94.

Check Out Our Latest Research Report on RXST

RxSight Price Performance

The company has a market capitalization of $193.30 million, a P/E ratio of -3.60 and a beta of 1.21. The business's 50-day moving average price is $4.93 and its two-hundred day moving average price is $6.07.

RxSight (NASDAQ:RXST - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). RxSight had a negative return on equity of 20.11% and a negative net margin of 43.80%. The business had revenue of $24.59 million for the quarter, compared to the consensus estimate of $27.19 million. Research analysts expect that RxSight, Inc. will post -0.78 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Mark Wilterding sold 7,765 shares of the company's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total value of $54,044.40. Following the transaction, the chief financial officer owned 25,049 shares in the company, valued at approximately $174,341.04. This represents a 23.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ronald M. Md Kurtz sold 5,100 shares of RxSight stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the sale, the insider directly owned 71,775 shares of the company's stock, valued at approximately $499,554. The trade was a 6.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 16,947 shares of company stock valued at $117,951. Corporate insiders own 10.05% of the company's stock.

Institutional Trading of RxSight

Several institutional investors and hedge funds have recently modified their holdings of RXST. BlackRock Inc. acquired a new stake in shares of RxSight during the 2nd quarter valued at $27,910,000. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in RxSight by 761.0% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,131,400 shares of the company's stock worth $6,969,000 after purchasing an additional 1,000,000 shares in the last quarter. Grandeur Peak Global Advisors LLC bought a new position in shares of RxSight during the second quarter valued at about $3,482,000. Deutsche Bank AG bought a new stake in shares of RxSight during the 2nd quarter worth $2,604,000. Finally, Bank of America Corp DE purchased a new position in shares of RxSight during the 2nd quarter valued at $2,339,000. 78.78% of the stock is currently owned by institutional investors.

About RxSight

(Get Free Report)

RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient's vision. Adjustments are made with RxSight's Light Delivery Device, which uses ultraviolet light to change the lens's optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in RxSight Right Now?

Before you consider RxSight, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.

While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines